- ISIN
- NL0015285941
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 2, 2020
Highlights
- Market Cap
- $1.32B
- Enterprise Value
- $992.32M
- EPS (TTM)
- -€1.71
- Total Revenue (TTM)
- €37.42M
- Gross Profit (TTM)
- €29.69M
- EBITDA (TTM)
- -€211.98M
- Year Range
- $5.05 - $12.41
- Target Price
- $21.00
- ROA (TTM)
- -39.60%
- ROE (TTM)
- -47.20%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
IMTX Performance Chart
Immatics N.V. (IMTX) is down 6.9% since the beginning of the year. At $10 per share, IMTX is trading 21.2% below its 52-week high of $12. Investors who bought $1,000 worth of IMTX shares 5 years ago would now be looking at an investment worth $837.
Loading charts...
Returns By Period
Immatics N.V. (IMTX) has returned -6.86% so far this year and 74.33% over the past 12 months.
Immatics N.V.
- 1D
- 0.00%
- 1M
- -15.83%
- YTD
- -6.86%
- 6M
- -5.51%
- 1Y
- 74.33%
- 3Y*
- -5.64%
- 5Y*
- -3.50%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
IMTX Monthly Returns History
Based on dividend-adjusted daily data since Jul 2, 2020, IMTX's average daily return is +0.03%, while the average monthly return is +0.59%. At this rate, an investment would double in approximately 9.8 years.
Historically, 51% of months were positive and 49% were negative. The best month was Sep 2025 with a return of +67.4%, while the worst month was Oct 2023 at -33.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.
On a daily basis, IMTX closed higher 48% of trading days. The best single day was May 2, 2023 with a return of +27.5%, while the worst single day was Oct 10, 2024 at -15.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -9.05% | 8.27% | -4.84% | 11.69% | 4.73% | -15.03% | -6.86% | ||||||
| 2025 | -23.07% | -19.93% | 2.97% | 10.86% | 7.80% | -0.19% | 19.89% | -21.09% | 67.39% | 19.60% | 4.91% | -1.78% | 47.68% |
| 2024 | 7.88% | 10.12% | -15.99% | -5.52% | 11.08% | 5.35% | 3.44% | -7.74% | 2.89% | -20.25% | -8.57% | -14.54% | -32.48% |
| 2023 | -6.89% | 4.44% | -18.54% | 3.62% | 38.04% | 16.92% | 3.21% | -0.59% | -2.20% | -33.94% | 15.56% | 19.12% | 20.90% |
| 2022 | -24.93% | -20.71% | -0.12% | -2.75% | -6.44% | 19.81% | 27.44% | 14.95% | -21.63% | 13.00% | -6.73% | -17.36% | -35.19% |
| 2021 | -1.48% | 1.51% | 3.89% | 9.01% | -8.10% | 3.38% | 5.17% | 8.76% | -2.11% | 10.23% | -20.66% | 18.21% | 24.56% |
Benchmark Metrics
Immatics N.V. has an annualized alpha of -7.14%, beta of 0.97, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since July 02, 2020.
- This stock participated in 164.16% of S&P 500 Index downside but only 73.95% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -7.14%
- Beta
- 0.97
- R²
- 0.08
- Upside Capture
- 73.95%
- Downside Capture
- 164.16%
Return for Risk
Risk / Return Rank
IMTX ranks 76 for risk / return — better than 76% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Immatics N.V. (IMTX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| IMTX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.85 | ||
| Sortino ratioReturn per unit of downside risk | -0.85 | ||
| Omega ratioGain probability vs. loss probability | 1.23 | 1.37 | -0.14 |
| Calmar ratioReturn relative to maximum drawdown | 2.69 | 2.78 | -0.10 |
| Martin ratioReturn relative to average drawdown | 5.89 | 12.44 | -6.55 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Immatics N.V.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Immatics N.V. was 77.78%, occurring on Apr 4, 2025. The portfolio has not yet recovered.
The current Immatics N.V. drawdown is 37.90%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -77.78%Apr 2025 | 4y 9mo | — | 5y 11moJul 2020 - now |
Drawdown Indicators
| IMTX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -77.78% | -56.78% | -21.00% |
Max Drawdown (1Y)Largest decline over 1 year | -27.80% | -9.10% | -18.70% |
Max Drawdown (3Y)Largest decline over 3 years | -74.05% | -18.90% | -55.15% |
Max Drawdown (5Y)Largest decline over 5 years | -77.36% | -25.43% | -51.93% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -37.90% | -1.80% | -36.10% |
Average DrawdownAverage peak-to-trough decline | -37.40% | -10.71% | -26.69% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.66% | 2.03% | +10.63% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Immatics N.V. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Immatics N.V. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for IMTX relative to other companies in the Biotechnology industry. Currently, IMTX has a P/S ratio of 28.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for IMTX in comparison with other companies in the Biotechnology industry. Currently, IMTX has a P/B value of 2.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with IMTX
Add Immatics N.V. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with IMTX